Article Figures & Data
Figures
- FIGURE 1.
Dasatinib had no effect on A549-fLuc tumor growth inhibition. (A) Tumor growth curves of A549-fLuc tumor–bearing mice administered vehicle control or dasatinib daily for 6 d (n = 7/group). Inset, schedule of dasatinib treatment and molecular imaging experiments. (B) Representative bioluminescence images and tumor BLI signal intensity changes from baseline to after treatment in the A549-fLuc tumor–bearing mice (n = 7/group). Arrows indicate location of tumors.
- FIGURE 2.
18F-FDG PET imaging revealed comparable tumor cell metabolism in A549-fLuc tumors with or without dasatinib treatment. (A) Representative small-animal PET images and relative tumor 18F-FDG uptake (posttreatment/baseline ratios) in A549-fLuc tumor–bearing mice (n = 5/group). Arrows indicate location of tumors. (B) Quantified GLUT-1 fluorescence intensity and quantified percentage of Ki-67–positive cells of the A549-fLuc tumor tissues with or without dasatinib treatment.
- FIGURE 3.
99mTc-3PRGD2 SPECT/CT imaging revealed decreased murine integrin β3 expression and inactivated integrin αvβ3 after dasatinib treatment. (A and B) Representative small-animal SPECT/CT images (A) and relative tumor 99mTc-3PRGD2 uptake (posttreatment/baseline ratios; B) in A549-fLuc tumor–bearing mice (n = 5/group). Arrows indicate location of tumors. (C) Quantified human integrin αvβ3 fluorescence intensity and quantified density of murine integrin β3–positive vessels in dasatinib-treated and control A549-fLuc tumor tissues. (D) 125I-c(RGDyK) radioligand binding assay in dasatinib-treated and control A549-fLuc tumor cells. *P < 0.05. ***P < 0.001.
- FIGURE 4.
NIRF imaging using Dye755-Ran revealed antiangiogenic effects of dasatinib. (A) Representative NIRF images and relative tumor Dye755-Ran uptake (posttreatment/baseline ratios) in A549-fLuc tumor–bearing mice (n = 7/group). Arrows indicate location of tumors. (B) Quantified human VEGF fluorescence intensity in dasatinib-treated and control A549-fLuc tumor tissues. (C) Representative Matrigel plugs harvested from nude mice after 7 d of inoculation. Control (−) = Matrigel only; control (+) = Matrigel mixed with dimethyl sulfoxide (vehicle control) and growth factors; dasatinib = Matrigel mixed with dasatinib and growth factors. *P < 0.05. **P < 0.01.
- FIGURE 5.
Significant improvements were observed in in vivo antitumor effects when combining dasatinib and DTX. (A) Tumor growth curves of A549-fLuc tumor–bearing mice that received daily administration of vehicle control, dasatinib, DTX, or dasatinib plus DTX (Das + DTX) for 6 d (n = 7/group). Inset, schedule of combination treatment and molecular imaging experiments. (B) Immunofluorescence staining of Ki-67 and quantified percentage of Ki-67–positive cells in A549-fLuc tumor tissues harvested from mice treated with vehicle (control), dasatinib (Das), DTX, and dasatinib plus DTX (Das + DTX) daily for 6 d. (C) Quantified tumor uptake (percentage injected dose per gram) of 18F-FDG, tumor-to-muscle ratios of 99mTc-3PRGD2, and tumor fluorescence intensity (radiance efficacy) of Dye755-Ran in A549-fLuc tumor–bearing nude mice with or without dasatinib plus docetaxel (Das + DTX) treatment for 6 d (n = 5/group). *P < 0.05. **P < 0.01. ***P < 0.001.
Additional Files
Supplemental Data
Files in this Data Supplement:
